Literature DB >> 6145399

Tardive dyskinesia. A discontinuation study.

W M Glazer, D C Moore, N R Schooler, L M Brenner, H Morgenstern.   

Abstract

Twenty-one nonschizophrenic and 12 schizophrenic outpatients with tardive dyskinesia (TD) were followed up for a mean of 12.0 and 8.6 months, respectively, following discontinuation of neuroleptic therapy. Of the 33 patients, only one demonstrated complete reversal of TD. Cumulative survival curves of the length of time to first improvement (reduction in movement ratings by 50% of baseline) did not differ between the two groups. The median time to first improvement was seven months. If a patient can be kept off of a neuroleptic regimen for 18 months, the estimated probability of showing a 50% reduction in movement is 87.2%. In the nonschizophrenic group, depressed mood was negatively correlated with severity of abnormal movements.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6145399     DOI: 10.1001/archpsyc.1984.01790170097011

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  10 in total

1.  Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial.

Authors:  Stanley N Caroff; Irene Hurford; Janice Lybrand; E Cabrina Campbell
Journal:  Neurol Clin       Date:  2011-02       Impact factor: 3.806

2.  Treatment Recommendations for Tardive Dyskinesia.

Authors:  Lucia Ricciardi; Tamara Pringsheim; Thomas R E Barnes; Davide Martino; David Gardner; Gary Remington; Donald Addington; Francesca Morgante; Norman Poole; Alan Carson; Mark Edwards
Journal:  Can J Psychiatry       Date:  2019-02-21       Impact factor: 4.356

Review 3.  Metabolism, pharmacogenetics, and metabolic drug-drug interactions of antipsychotic drugs.

Authors:  J Fang; J W Gorrod
Journal:  Cell Mol Neurobiol       Date:  1999-08       Impact factor: 5.046

Review 4.  Movement disorders of the mouth: a review of the common phenomenologies.

Authors:  C M Ghadery; L V Kalia; B S Connolly
Journal:  J Neurol       Date:  2022-07-29       Impact factor: 6.682

5.  The impact of neuroleptic medication on tardive dyskinesia: a meta-analysis of published studies.

Authors:  H Morgenstern; W M Glazer; D Niedzwiecki; P Nourjah
Journal:  Am J Public Health       Date:  1987-06       Impact factor: 9.308

6.  Metabolic studies on haloperidol and its tetrahydropyridinyl dehydration product (HPTP) in C57BL/6 mouse brain preparations.

Authors:  Etsuko Usuki; Jeffrey R Bloomquist; Ethan Freeborn; Kay Casagnoli; Cornelis J Van Der Schyf; Neal Castagnoli
Journal:  Neurotox Res       Date:  2002-02       Impact factor: 3.911

Review 7.  Antipsychotic reduction and/or cessation and antipsychotics as specific treatments for tardive dyskinesia.

Authors:  Hanna Bergman; John Rathbone; Vivek Agarwal; Karla Soares-Weiser
Journal:  Cochrane Database Syst Rev       Date:  2018-02-06

8.  Tardive Syndromes are Rarely Reversible after Discontinuing Dopamine Receptor Blocking Agents: Experience from a University-based Movement Disorder Clinic.

Authors:  Deepti Zutshi; Leslie J Cloud; Stewart A Factor
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2014-10-23

9.  Hospital utilization rates following antipsychotic dose reduction in mood disorders: implications for treatment of tardive dyskinesia.

Authors:  Stanley N Caroff; Fan Mu; Rajeev Ayyagari; Traci Schilling; Victor Abler; Benjamin Carroll
Journal:  BMC Psychiatry       Date:  2020-07-11       Impact factor: 3.630

10.  Hospital utilization rates following antipsychotic dose reductions: implications for tardive dyskinesia.

Authors:  Stanley N Caroff; Fan Mu; Rajeev Ayyagari; Traci Schilling; Victor Abler; Benjamin Carroll
Journal:  BMC Psychiatry       Date:  2018-09-24       Impact factor: 3.630

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.